Hawthorn extract for treating chronic heart failure
- PMID: 18254076
- DOI: 10.1002/14651858.CD005312.pub2
Hawthorn extract for treating chronic heart failure
Abstract
Background: Hawthorn extract is advocated as an oral treatment option for chronic heart failure. Also, the German Commission E approved the use of extracts of hawthorn leaf with flower in patients suffering from heart failure graded stage II according to the New York Heart Association.
Objectives: To assess the benefits and harms as reported in double-blind randomised clinical trials of hawthorn extract compared with placebo for treating patients with chronic heart failure.
Search strategy: We searched CENTRAL on The Cochrane Library (issue 2, 2006), MEDLINE (1951 to June 2006), EMBASE (1974 to June 2006), CINAHL (1982 to June 2006) and AMED (1985 to June 2006). Experts and manufacturers were contacted. Language restrictions were not imposed.
Selection criteria: To be included, studies were required to state that they were randomised, double-blind, and placebo controlled, and used hawthorn leaf and flower extract monopreparations.
Data collection and analysis: Two reviewers independently performed the selection of studies, data extraction, and assessment of methodological quality. Data were entered into RevMan 4.2 software. Results from continuous data were reported as weighted mean difference (WMD) with 95% confidence interval (CI). Where data were suitable for combining, pooled results were calculated.
Main results: Fourteen trials met all inclusion criteria and were included in this review. In most of the studies, hawthorn was used as an adjunct to conventional treatment. Ten trials including 855 patients with chronic heart failure (New York Heart Association classes I to III) provided data that were suitable for meta-analysis. For the physiologic outcome of maximal workload, treatment with hawthorn extract was more beneficial than placebo (WMD (Watt) 5.35, 95% CI 0.71 to 10.00, P < 0.02, n = 380). Exercise tolerance were significantly increased by hawthorn extract (WMD (Watt x min) 122.76, 95% CI 32.74 to 212.78, n = 98). The pressure-heart rate product, an index of cardiac oxygen consumption, also showed a beneficial decrease with hawthorn treatment (WMD (mmHg/min) -19.22, 95% CI -30.46 to -7.98, n = 264). Symptoms such as shortness of breath and fatigue improved significantly with hawthorn treatment as compared with placebo (WMD -5.47, 95% CI -8.68 to -2.26, n = 239). No data on relevant mortality and morbidity such as cardiac events were reported, apart from one trial, which reported deaths (three in active, one in control) without providing further details. Reported adverse events were infrequent, mild, and transient; they included nausea, dizziness, and cardiac and gastrointestinal complaints.
Authors' conclusions: These results suggest that there is a significant benefit in symptom control and physiologic outcomes from hawthorn extract as an adjunctive treatment for chronic heart failure.
Similar articles
-
Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials.Am J Med. 2003 Jun 1;114(8):665-74. doi: 10.1016/s0002-9343(03)00131-1. Am J Med. 2003. PMID: 12798455
-
Adverse-event profile of Crataegus spp.: a systematic review.Drug Saf. 2006;29(6):523-35. doi: 10.2165/00002018-200629060-00005. Drug Saf. 2006. PMID: 16752934 Review.
-
Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442.Forsch Komplementarmed Klass Naturheilkd. 2004 Aug;11 Suppl 1:36-9. doi: 10.1159/000080574. Forsch Komplementarmed Klass Naturheilkd. 2004. PMID: 15353901
-
Horse chestnut seed extract for chronic venous insufficiency.Cochrane Database Syst Rev. 2002;(1):CD003230. doi: 10.1002/14651858.CD003230. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2004;(2):CD003230. doi: 10.1002/14651858.CD003230.pub2. PMID: 11869657 Updated. Review.
-
Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial.Eur J Heart Fail. 2009 Oct;11(10):990-9. doi: 10.1093/eurjhf/hfp116. Eur J Heart Fail. 2009. PMID: 19789403 Free PMC article. Clinical Trial.
Cited by
-
Characterizations of White Mulberry, Sea-Buckthorn, Garlic, Lily of the Valley, Motherwort, and Hawthorn as Potential Candidates for Managing Cardiovascular Disease-In Vitro and Ex Vivo Animal Studies.Nutrients. 2024 Apr 27;16(9):1313. doi: 10.3390/nu16091313. Nutrients. 2024. PMID: 38732560 Free PMC article. Review.
-
Tejocote Root's Role in Symptomatic Mobitz Type 1 Heart Block: A Compelling Case Report.Cureus. 2023 Sep 14;15(9):e45228. doi: 10.7759/cureus.45228. eCollection 2023 Sep. Cureus. 2023. PMID: 37842399 Free PMC article.
-
Effect of E-OJ-01 on Left Ventricular Ejection Fraction and Myocardial Oxygen Consumption: A Randomized, Double-Blind, Placebo-Controlled Study.J Multidiscip Healthc. 2022 Nov 2;15:2511-2525. doi: 10.2147/JMDH.S381028. eCollection 2022. J Multidiscip Healthc. 2022. PMID: 36349244 Free PMC article.
-
Fatal arrhythmia following ingestion of hawthorn root (Crataegus pubescens) extract: a case report.Clin Exp Emerg Med. 2022 Dec;9(4):373-376. doi: 10.15441/ceem.21.086. Epub 2022 Jul 22. Clin Exp Emerg Med. 2022. PMID: 35863376 Free PMC article.
-
Illumina-Based Analysis Yields New Insights Into the Fungal Contamination Associated With the Processed Products of Crataegi Fructus.Front Nutr. 2022 May 12;9:883698. doi: 10.3389/fnut.2022.883698. eCollection 2022. Front Nutr. 2022. PMID: 35634418 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous